[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.194.190. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

August 2019 - April 2015

Decade

Year

Issue

May 2019, Vol 5, No. 5, Pages 592-750

Original Investigation

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(5):623-632. doi:10.1001/jamaoncol.2018.6607

This randomized clinical trial compares the use of combined androgen-deprivation therapy plus docetaxel with androgen-deprivation therapy alone in patients with prostate cancer who develop increasing levels of prostate-specific antigen after primary local therapy.

Association of Digital Breast Tomosynthesis vs Digital Mammography With Cancer Detection and Recall Rates by Age and Breast Density

Abstract Full Text
JAMA Oncol. 2019;5(5):635-642. doi:10.1001/jamaoncol.2018.7078

This cohort study compares cancer detection rate by patient age and breast density as well as cancer detection and prognosis outcomes when using digital breast tomosynthesis vs digital mammography alone for breast cancer screening.

Effect of Collaborative Telerehabilitation on Functional Impairment and Pain Among Patients With Advanced-Stage Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(5):644-652. doi:10.1001/jamaoncol.2019.0011

This randomized clinical trial assesses whether telerehabilitation alone or combined with pharmacological pain management improves function, lessens pain, and reduces requirements for inpatient care in patients with advanced-stage cancer.

Use of Crowd Innovation to Develop an Artificial Intelligence–Based Solution for Radiation Therapy Targeting

Abstract Full Text
open access
JAMA Oncol. 2019;5(5):654-661. doi:10.1001/jamaoncol.2019.0159

This study compares a crowdsourced artificial intelligence solution for segmenting lung tumors for radiation therapy with expert radiation oncologists.

Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(5):664-670. doi:10.1001/jamaoncol.2018.6752

This phase 3 randomized clinical trial assesses differences in health-related quality of life between men with low-risk prostate cancer who are treated with hypofractionated vs conventional radiotherapy.

Incidence of and Risk Factors for Histologically Confirmed Solid Benign Tumors Among Long-term Survivors of Childhood Cancer

Abstract Full Text
JAMA Oncol. 2019;5(5):671-680. doi:10.1001/jamaoncol.2018.6862

This Dutch national record linkage study quantifies the incidence of and treatment-related risk factors for histologically confirmed solid nonskin benign tumors among survivors of childhood cancer.

Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer: A Phase 2 Clinical Trial

Abstract Full Text
has audio
JAMA Oncol. 2019;5(5):681-688. doi:10.1001/jamaoncol.2018.6993

This phase 2 clinical trial examines the outcomes of patients with early-stage non–small cell lung cancer receiving neoadjuvant stereotactic ablative radiotherapy followed by surgery.

Association of Combined Modality Therapy vs Chemotherapy Alone With Overall Survival in Early-Stage Pediatric Hodgkin Lymphoma

Abstract Full Text
JAMA Oncol. 2019;5(5):689-695. doi:10.1001/jamaoncol.2018.5911

This cohort study uses data from the National Cancer Database to examine the use of combined modality therapy in pediatric Hodgkin lymphoma and its association with overall survival.

Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel

Abstract Full Text
open access
JAMA Oncol. 2019;5(5):696-702. doi:10.1001/jamaoncol.2018.7098

This study explores whether blood tumor mutational burden estimated by a next-generation sequencing gene panel is associated with clinical outcomes of patients with non–small cell lung cancer treated with anti–programmed cell death 1 and anti–programmed cell death ligand 1 agents.

Association of Neurosurgical Resection With Development of Pachymeningeal Seeding in Patients With Brain Metastases

Abstract Full Text
JAMA Oncol. 2019;5(5):703-709. doi:10.1001/jamaoncol.2018.7204

This cohort study assesses the association and incidence of pachymeningeal seeding after neurosurgical resection in patients with brain metastases treated with adjuvant stereotactic radiation.

Brief Report

Effect of Aerobic and Resistance Exercise Intervention on Cardiovascular Disease Risk in Women With Early-Stage Breast Cancer: A Randomized Clinical Trial

Abstract Full Text
JAMA Oncol. 2019;5(5):710-714. doi:10.1001/jamaoncol.2019.0038

This randomized clinical trial examines whether an exercise intervention improves the Framingham Risk Score for cardiovascular disease among women with early-stage breast cancer with overweight condition or obesity.

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

Abstract Full Text
open access online only
JAMA Oncol. 2019;5(5):e190339. doi:10.1001/jamaoncol.2019.0339

This final analysis of the phase 3 randomized clinical trial HannaH evaluates the efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2-positive early breast cancer after 6 years’ follow-up.

Research Letter

US National Trends in Opioid-Related Hospitalizations Among Patients With Cancer

Abstract Full Text
JAMA Oncol. 2019;5(5):734-735. doi:10.1001/jamaoncol.2019.0042

This study evaluates the patient demographics and clinical characteristics of 14 095 opioid-related hospitalizations from the US National Inpatient Sample (NIS) of the Healthcare Cost and Utilization Project (HCUP).

Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States

Abstract Full Text
JAMA Oncol. 2019;5(5):735-737. doi:10.1001/jamaoncol.2019.0349

This cross-sectional study analyzes the proportion of patients with cancer and cancer survivors who use complementary and alternative medicine (CAM) without disclosing this information to their physicians.

Analysis of Toxic Effects With Antiangiogenic Agents Plus Stereotactic Body Radiation in Ultracentral Lung Tumors

Abstract Full Text
JAMA Oncol. 2019;5(5):737-739. doi:10.1001/jamaoncol.2019.0205

This case series analyzes the association between antiangiogenic agents plus stereotactic body radiation for ultracentral lung tumors and toxic effects.

Special Communication

Maintenance Therapies for Hodgkin and Non-Hodgkin Lymphomas After Autologous Transplantation: A Consensus Project of ASBMT, CIBMTR, and the Lymphoma Working Party of EBMT

Abstract Full Text
JAMA Oncol. 2019;5(5):715-722. doi:10.1001/jamaoncol.2018.6278

This consensus project reports the findings of the American Society for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation expert panel, which convened to formulate consensus recommendations regarding the use of maintenance and/or consolidation therapies after autologous hematopoietic cell transplantation in patients with lymphoma.

Review

The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Made Simple for Medical and Radiation Oncologists: A Narrative Review

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(5):723-727. doi:10.1001/jamaoncol.2018.5631

This review describes the structure and requirements of the Medicare Access and CHIP [Children’s Health Insurance Program] Reauthorization Act of 2015 and how it affects reimbursement for medical and radiation oncologists.

JAMA Oncology Clinical Challenge

Multiple Lesions in Irradiated Skin

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(5):728-729. doi:10.1001/jamaoncol.2018.5852

A white man in his 20s with a history of medulloblastoma and meningioma presented with multiple pink and brown papules and plaques on the head, neck, and back. What is your diagnosis?

Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy

Abstract Full Text
has active quiz
JAMA Oncol. 2019;5(5):730-731. doi:10.1001/jamaoncol.2018.6431

A 41-year-old woman with stage IIa melanoma of the upper thigh presented with diffuse erythematous induration of the upper thigh expanding to the lower left abdominal area and palpable subcutaneous nodules on the ipsilateral gluteal region and leg during nivolumab therapy. What is your diagnosis?

Viewpoint

Unintended Consequences of the Right to Try Act for Palliative Care in Pediatric Oncology

Abstract Full Text
JAMA Oncol. 2019;5(5):603-604. doi:10.1001/jamaoncol.2018.7201

This Viewpoint highlights potential unintended consequences that the Right to Try Act may have on palliative care for pediatric patients with cancer.

HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer

Abstract Full Text
JAMA Oncol. 2019;5(5):605-606. doi:10.1001/jamaoncol.2018.7229

This Viewpoint questions a recently published treatment algorithm for patients with HER2-amplified metastatic colorectal cancer and proposes alternative timing for HER2 testing and HER2-directed therapies.

US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology: A Dangerous Precedent?

Abstract Full Text
JAMA Oncol. 2019;5(5):607-608. doi:10.1001/jamaoncol.2019.0093

This Viewpoint highlights the drawbacks of US Food and Drug Administration approval of lenvatinib for unresectable hepatocellular cancer based on the results of a noninferiority trial.

Editorial

JAMA Oncology—The Year in Review, 2018

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):609-610. doi:10.1001/jamaoncol.2019.0231
Invited Commentary

Adjuvant Androgen-Deprivation Therapy for Prostate Cancer: Should Docetaxel Be Added?

Abstract Full Text
JAMA Oncol. 2019;5(5):633-634. doi:10.1001/jamaoncol.2018.6604

Breast Cancer Screening Using Digital Breast Tomosynthesis: Not All Mammography Is Equal

Abstract Full Text
JAMA Oncol. 2019;5(5):642-643. doi:10.1001/jamaoncol.2018.7056

Collaborative Telerehabilitation—A Smart Move for Patients With Advanced Cancer

Abstract Full Text
JAMA Oncol. 2019;5(5):652-653. doi:10.1001/jamaoncol.2019.0021

The Potential and Pitfalls of Crowdsourced Algorithm Development in Radiation Oncology

Abstract Full Text
JAMA Oncol. 2019;5(5):662-663. doi:10.1001/jamaoncol.2019.0157
Editor's Note

Scientific Integrity and Data Accuracy

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):745. doi:10.1001/jamaoncol.2019.0656

This note from the editors commends the honesty of authors who exemplify scientific integrity by having reported data errors in their article, which was retracted.

JAMA Oncology Patient Page

Chemotherapy-Induced Peripheral Neuropathy

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):750. doi:10.1001/jamaoncol.2018.6771

This patient page describes the risks, symptoms, complications, and recommended treatment options for chemotherapy-induced peripheral neuropathy.

Poetry and Oncology

Beat of the Same Drum

Abstract Full Text
JAMA Oncol. 2019;5(5):663. doi:10.1001/jamaoncol.2018.7167
Comment & Response

Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer—Beyond the Misdiagnosis

Abstract Full Text
JAMA Oncol. 2019;5(5):739-740. doi:10.1001/jamaoncol.2019.0518

Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer—Beyond the Misdiagnosis

Abstract Full Text
JAMA Oncol. 2019;5(5):740-741. doi:10.1001/jamaoncol.2019.0521

Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer—Beyond the Misdiagnosis—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(5):741. doi:10.1001/jamaoncol.2019.0536

Undissected Axilla and Axillary Radiotherapy

Abstract Full Text
JAMA Oncol. 2019;5(5):741-742. doi:10.1001/jamaoncol.2019.0031

Undissected Axilla and Axillary Radiotherapy—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(5):742-743. doi:10.1001/jamaoncol.2019.0050

Hyperprogression—Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer

Abstract Full Text
JAMA Oncol. 2019;5(5):743. doi:10.1001/jamaoncol.2019.0130

Hyperprogression—Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer—In Reply

Abstract Full Text
JAMA Oncol. 2019;5(5):744. doi:10.1001/jamaoncol.2019.0138

Notice of Retraction. Maret-Ouda et al. Risk of Esophageal Adenocarcinoma After Antireflux Surgery in Patients With Gastroesophageal Reflux Disease in the Nordic Countries. JAMA Oncol. 2018;4(11):1576-1582

Abstract Full Text
JAMA Oncol. 2019;5(5):744-745. doi:10.1001/jamaoncol.2019.0653
Correction

Error in Order of Authors in Byline

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):745. doi:10.1001/jamaoncol.2019.0706

Error in Author’s Name

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):745. doi:10.1001/jamaoncol.2019.0810

Incorrect Author Affiliation

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):745. doi:10.1001/jamaoncol.2019.1384
JAMA Oncology Masthead

JAMA Oncology

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):599. doi:10.1001/jamaoncol.2018.4756
Peer Reviewers List

JAMA Oncology Peer Reviewers in 2018

Abstract Full Text
free access online only
JAMA Oncol. 2019;5(5):e190109. doi:10.1001/jamaoncol.2019.0109
In This Issue of JAMA Oncology

Highlights

Abstract Full Text
free access
JAMA Oncol. 2019;5(5):592. doi:10.1001/jamaoncol.2018.4755
×